Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
J2H Biotech Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, O DELL, DAVID K, who is responsible for the pending office action. The prosecution is being conducted within 1 distinct art unit. Because of this pending action, the company's immediate focus is concentrated on the specific requirements of the examiner and art unit.
The busiest examiner, O DELL, DAVID K, is the primary point of contact for the 1 pending action. For the practitioner, this means that the outcome of the current prosecution depends on the examination style and technical interpretations of this individual. The alignment of the pending action with the examiner and art unit reflects a narrow and specific interaction with the patent office at this time. This concentration allows for a focused strategy when addressing the outstanding Biotechnology & Pharmaceuticals application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565704 | PHARMACEUTICAL PREPARATION FOR PREVENTING OR TREATING PULMONARY FIBROSIS | O DELL, DAVID K | 20d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18565704 | PHARMACEUTICAL PREPARATION FOR PREVENTING OR TREATING PULMONARY FIBROSIS | O DELL, DAVID K | 1621 | §103§112DP | Final Rejection | 20d | Pending | Nov 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial